CareDx director Hannah Valantine sells $279,728 in stock

CareDx director Hannah Valantine sold 12,103 shares on June 15, 2026 for about $279,728 at a weighted average price of $23.1123, following a June 12 RSU vesting of 9,795 shares and leaving her with 36,686 shares. The article also highlights strong Q1 2026 results, with EPS of $0.34 versus -$0.06 expected and revenue of $117.7 million versus $104.12 million, plus BTIG's raised $28 price target after the up to $260 million Naveris acquisition. Overall, the tone is constructive for fundamentals but tempered by insider selling and a stock already near its 52-week high.

Analysis

CDNA is being treated like a post-earnings momentum name, but the better lens is that the stock is now pricing a cleaner execution path just as management is layering in M&A and equity dilution. The Naveris deal likely helps broaden the narrative from a single-test story into a more diversified transplant/onco-monitoring platform, but it also increases integration risk right when the market is rewarding “beat-and-raise” quality rather than proof-of-concept. The insider sale looks routine in isolation, yet after a sharp run and near-high trading, it reinforces that upside from here depends less on multiple expansion and more on sustained operating leverage.

The second-order issue is capital allocation. An equity incentive expansion plus acquisition consideration implies that per-share value creation now depends on whether incremental revenue growth outpaces share count creep and deal-related synergies. If gross margin or opex discipline slips even modestly over the next 2-3 quarters, the market can re-rate the stock quickly because expectations have shifted from recovery to proof.

The contrarian take is that consensus may be underestimating how much of the good news is already in the tape. A high short-term measured move after earnings, M&A, and analyst target resets often leaves the stock vulnerable to a flat quarter or any sign that testing growth is normalizing. The more interesting upside case is not simply “better results,” but a sustained acceleration in clinical adoption or a material contribution from Naveris that changes the long-term revenue mix over the next 6-12 months.

Key Decisions for Investors

• Short-term: take profits on existing CDNA longs into strength; use the next 2-4 weeks to reduce exposure if the stock holds near highs without fresh upward estimate revisions.
• If initiating new risk, prefer a call spread over outright stock: buy CDNA 3-6 month ATM calls / sell 20-25% OTM calls to express upside while capping premium burn if post-earnings momentum fades.
• Pair trade: long CDNA vs short a slower-growth diagnostics peer with weaker execution quality over the next 1-2 quarters; the trade works only if CDNA keeps showing revenue beats and margin discipline.
• Watch for a post-deal integration tell: if Naveris-related commentary in the next two earnings calls is vague on synergies or timeline, fade the stock on any spike above the recent range.
• Avoid chasing on insider-sale headlines alone; use any 5-8% pullback after the current run as the only acceptable entry, and only if channel checks still support transplant-testing demand.